 |
|||
| Ehrlich II 2008 Workshop Program | |||
| The workshop program at the Ehrlich I meeting
in 2004 was a great success and we are very pleased having many of the
world class scientists and thought leaders in their fields to give the
workshops at the Ehrlich II 2008 world conference.
Workshop participants will get the opportunity to hear a large variety
of topics and opinions from a variety of perspectives and can personally
discuss their questions with the professors in the question and answer
sessions. This program offers great opportunities to make the first
steps in a new field, get new knowledge, or learn about the pulse of
cutting-edge research by leading scientists. |
|||
|
Friday – morning, October 3, 2008 |
|||
|
Time
|
Basic Concepts of pharmacokinetics (PK) and Pharmacodynamics (PD) | Clinical Aspects & Applications of PK/PD | WHOLE DAY BIOANALYTICAL WORKSHOP – Theory and Hands-on |
|
8:00AM
|
PK1: Basic concepts in pharmacokinetics Dr. Carl Kirkpatrick, 45 min From human physiology, absorption / sampling sites, and routes of elimination to the clearance & volume of distribution concept |
ClinPK1: Introduction and Overview into
PK/PD for patients, Dr. Roger Jelliffe,
45 min Optimizing individualized patient therapy using nonparametric PK and PD models, multiple model (MM) dosage design, and Bayesian adaptive control. |
Lecture on Chromatography in biomedical
sciences, Dr. Matthias Unger, 45 min Basic principles, applications, intricacies of HPLC |
|
8:45AM
|
PD1: Basic principles in pharmacology Dr. Donald Mager, 45 min Receptor occupancy theory, Hill equation, Examples of effect vs. concentration profiles |
ClinPK2: Overview and comparison of parametric
and non-parametric estimation techniques, Drs.
Jelliffe & J. Bulitta, 45 min Differences in algorithms used to estimate parameters of PK/PD models |
Lecture on HPLC coupled with tandem mass
spectrometry (LC-MS/MS) Dr. Gérard Hopfgartner, 45 min Strengths, applications, and intricacies of LC-MS/MS for biomedical research |
|
9:30AM
|
Case study 1: Group discussion PK1, PD1
Drs. Kirkpatrick and Mager, 30 min |
Case study 1: Clinical problems. Solving
them using PK/PD Adaptive Control, 30 min MM dosage design, 4 types of Bayesian model individualization, and MM dosage adjustment. |
Practical Issues of Bioanalytical Problems
– How to Approach Assay Development, Drs. Unger & Hopfgartner |
|
10:00AM
|
Break (30 min) |
||
|
10:30AM
|
PK 2: Absorption & Elimination Processes
Dr. Carl Kirkpatrick, 45 min Determinants of rate & extent of absorption Hepatic, renal, and other routes of elimination |
ClinPK3: Therapeutic drug monitoring
– how does the patient benefit Dr. Alexander Vinks, 45 min How can therapy be optimized by measuring drug concentrations and PK/PD modeling |
Lecture on microdialysis: Measuring unbound
concentrations in tissues, Dr. Markus Zeitlinger, 45 min Microdialysis as a powerful and versatile tool to measure unbound concentrations |
|
11:15AM
|
PD 2: Pharmacokinetic / Pharmacodynamic
Concepts, Dr. William Jusko, 45 min Overview of basic and more advanced PK/PD models – when to consider which model? |
ClinPK4: Optimizing cardiovascular therapy,
Dr. Jelliffe, 45 min Example for use of modeling and individual therapy optimization (e.g. for digoxin) |
Lecture on bioanalytical techniques:
What do capillary electrophoresis (CE) and NMR spectrometry have to offer? Dr. Ulrike Holzgrabe, 45 min |
|
Noon
|
Case study 2: Group discussion PK2, PD2
Drs. Jusko and Kirkpatrick, 30 min |
Case study 2: Discussion of benefits and applications of PK/PD for patients, Drs. Vinks and Jelliffe, 30 min | Case study 3: Discussion of pros and
cons of various bioanalytical techniques, Drs. Zeitlinger and Holzgrabe, 30 min |
|
12:30PM
to 1:45PM |
Lunch break (75 min)
|
||
| Friday – afternoon and evening, October 3, 2008 | |||
|
Time
|
Basic Modeling & Simulation
(M&S) techniques |
Clinical Aspects & Applications of PK/PD
How to implement this approach in real-life |
Optimal therapy in special patient groups
|
|
1:45PM
|
M&S 1: Standard non-compartmental
analysis, Dr. Samer Mouksassi, 45
min Introduction to the most commonly used non-compartmental methods of PK data analysis |
ClinPK5: Therapeutics: optimizing learning
about the patient while treating him/her at the same time, Dr. Jelliffe, 45min How to maximize learning while treating |
Dose optimization for cancer patients Dr. Ulrich Jaehde, 40 min Overview and issues of PK principles and applications for cancer therapy |
|
2:30PM
|
M&S 2: Design, analysis, and key
aspects of bioequivalence studies, Dr. Helmut Schütz, 45 min Techniques and critical issues of bioequivalence assessment |
ClinPK6: PK/PD modeling to optimize anti-infective
therapy, Dr. Alan Forrest, 45min Transition from theory to real life: How can a physician / pharmacist apply population PK/PD models at the bedside (HIV patient examples) |
Dose optimization for pediatric patients Dr. Alexander Vinks, 40 min Using PK/PD to optimize therapy in children |
|
3:15PM
|
Group discussion: Practical discussion
on how to assess bioequivalence Drs. Mouksassi and Schütz, 30 min |
Group discussion: How to implement clinical
PK/PD modeling for patient care Drs. Jelliffe and Forrest, 30 min |
Individual differences in effects of
psychoactive drugs: Interactions, pharmacogenetics and other factors Dr. Julia Kirchheiner, 40 min |
|
3:45PM
to 4:30PM |
Afternoon Break
Focus on Software Demos (demos will be available during the whole meeting) |
||
|
Compartmental modeling and
Population PK/PD data analysis |
Monte Carlo Simulations and
Disease Progression Modeling |
Overview of PK/PD tools for estimation, optimal design, & clinical trial simulation | |
|
4:30PM
|
M&S 3: Introduction to Compartmental
Modeling and Simulations, Dr. Cornelia Landersdorfer, 45 min Highlighting differences and similarities to non-compartmental techniques |
M&S 5: Monte Carlo Simulations to
predict the behavior of a whole patient population Dr. Vincent Tam, 45 min What can we learn from incorporating between subject variability into simulations? |
M&S 7: Overview of PK/PD software
tools for estimation and optimal design Dr. Jürgen Bulitta, 30 min The most appropriate / feasible methods for each task – the pros & cons of PK/PD tools |
|
5:15PM
|
M&S 4: Concept and basic principles
of population PK modeling, Dr. Carl Kirkpatrick, 45 min How to best account for between subject variability & the effect of patient characteristics |
M&S 6: Combining PK/PD with disease
progression modeling, Dr. Cornelia Landersdorfer, 45 min Benefits of incorporating natural disease progression and long-term drug effects |
M&S 8: Non-parametric population
PK/PD tools for estimation and patient care Dr. Roger Jelliffe, 40 min How to achieve target goals most precisely – an efficient strategy for optimal patient care |
|
6:00PM
|
Group discussion: How to apply modeling
and simulation of clinical trials Drs. Kirkpatrick, 30 min |
Group discussion: How to integrate PK,
PD, disease progression via Monte Carlo sims. Drs. Tam and Landersdorfer, 30 min |
M&S 9: Clinical trial simulation
as a tool to design robust and effective clinical trials Dr. Samer Mouksassi, 50 min Pharsight Clinical Trial Simulator Case study |
| Workshop Mentor
Team (in alphabetical order):
1. Jürgen Bulitta |
|||